No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 25
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Eupraxia Pharmaceuticals Inc. (EPRX) stock was $7.75 as of Oct 6, 2026, 10:40 AM EDT.
Longer view (total return, dividends reinvested): past 12 months +32.3%
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Biotechnology · Victoria, BC
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.26
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.16
vs Estimate
$-0.23
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1EPRX | $259.30M | $7.75 | N/A | +32.30% | N/A | N/A | N/A |
| 2IKT | $259.44M | $1.97 | -1.75% | +20.37% | -29.10% | N/A | vs EPRX |
| 3EYPT | $258.48M | $3.08 | -2.13% | -76.90% | -21.68% | -20.02% | vs EPRX |
| 4ACIU | $258.00M | $2.54 | -6.46% | -31.95% | -16.03% | -16.61% | vs EPRX |
| 5ANIK | $256.48M | $19.16 | -2.86% | +116.73% | -13.40% | -8.51% | vs EPRX |
| 6IPSC | $253.80M | $1.40 | -5.30% | +186.88% | -42.05% | N/A | vs EPRX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 10 analysts
Average Price Target
$16.35
+111.1% upside
Low
$11.00
Current
$7.75
High
$25.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.47 | $-0.38 | $-0.32 | 7 |
| Quarter ending Dec 2026 | $-0.53 | $-0.41 | $-0.34 | 7 |
| Quarter ending Mar 2027 | $-0.36 | $-0.36 | $-0.36 | 2 |
| Quarter ending Jun 2027 | $-0.37 | $-0.37 | $-0.37 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.71 | $-1.25 | $-0.62 | 8 |
| FY 2027 | $-1.86 | $-1.41 | $-0.43 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $14.03M | $14.03M | $14.03M | 9 |
